Table 3 The results of the base case analyses comparing timing of price negotiations
From: The impact of early phase price agreements on prices of orphan drugs
Spinraza | Orkambi | ||||||
|---|---|---|---|---|---|---|---|
Actual price | € 240.000 | € 169,386 | |||||
Cost of capital | 9% | 7% | 5% | 9% | 7% | 5% | |
> Phase III | BE price | € 203,449 | € 181,040 | € 160,202 | € 143,589 | € 127,774 | € 113,066 |
Change | −15.2% | −24.6% | −33.2% | −15.2% | − 24.6% | − 33.2% | |
>Phase II | BE price | € 188,394 | € 159,123 | € 133,553 | € 132,964 | € 112,305 | € 94,259 |
Change | − 21.5% | −33.7% | −44.4% | −21.5% | − 33.7% | −44.4% |